Nifedipina Doc (Nifedipine)

Nifedipine belongs to the dihydropyridine class of calcium‑channel blockers. It selectively inhibits L‑type calcium channels in vascular smooth‑muscle cells, preventing calcium influx that is required for muscle contraction. This results in relaxation of arterial smooth muscle, vasodilation, reduced peripheral resistance, and lower arterial pressure. In coronary arteries, the same mechanism improves myocardial oxygen supply.

The appropriate dose of Nifedipina Doc is determined by the prescribing healthcare professional based on the individual patient's condition, response, and tolerability. Typical starting doses for hypertension or angina are established in clinical guidelines, but the exact regimen, including strength and frequency, must be set by the prescriber and adjusted as needed.

Safety data for nifedipine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their physician.

To place an order, visit the product page on gnhindia.com and submit an enquiry specifying the required quantity of Nifedipina Doc. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements) and assists with import documentation.

Nifedipina Doc, as a calcium‑channel blocker, primarily causes vasodilation, whereas beta‑blockers reduce cardiac output and ACE inhibitors block angiotensin‑II formation. Compared with other dihydropyridine agents, nifedipine has a rapid onset and is effective for both hypertension and angina. Choice of therapy depends on patient comorbidities, tolerability, and physician preference.

Store Nifedipina Doc at ambient temperature, preferably below 25 °C (77 °F). Keep the tablets in the original packaging, protect them from moisture, heat, and direct sunlight. Do not store in bathrooms or near kitchen appliances. Ensure the container is tightly closed to maintain product stability.

Nifedipina Doc is taken orally as a tablet. Swallow the tablet whole with a full glass of water; it may be taken with or without food. Do not crush, chew, or split the tablet unless specifically instructed by a healthcare professional. Follow the dosing schedule prescribed by the physician.

The most serious adverse events include severe hypotension, which can cause dizziness or fainting; myocardial infarction, particularly in patients with existing coronary artery disease; and allergic reactions such as rash, swelling, or anaphylaxis. Patients should seek immediate medical attention if they experience sudden weakness, chest pain, or signs of a severe allergic response.

Nifedipina Doc is contraindicated in individuals with known hypersensitivity to nifedipine or any excipients, as well as patients with severe aortic stenosis, cardiogenic shock, or uncontrolled heart failure. Caution is also advised for those taking potent CYP3A4 inhibitors or inducers without appropriate dose adjustments. Always consult a healthcare professional before starting therapy.